The company has built 185 million dirhams in its capital reserves to improve the liquidity of its action potential. The number of shares from 15 000 to 100 000. Its revenues tripled between 1999 and 2009.
After a slow recovery of IPOs in 2010 (with a total and for every two public offerings, namely CNIA Saada and ENNAKL), the coming year will be the start of the significant return of "paper expense". Indeed, no fewer than a half-dozen companies are preparing their plans of campaign market or already honing their briefs. After Stroc Industry, Meditel, Koutoubia and other operators who have announced their intention to join the side, a new truck, this time working in the pharmaceutical sector in Morocco, seems to sharpen its weapons to reach the coast.
This Laboratories Bottu which the shareholder, the family Berrada, just increase the capital from 15 to 200 million dirhams by incorporation of reserves. This operation, which does not change, nothing, certainly, the valuation of the company (no injection of new money) is to improve the liquidity of the action potential in Bottu in bringing the total to 100 000 (against only 15 000 previously) with a nominal value of 2,000 dirhams. A goal that soothes without doubt, the manufacturer of the famous Doliprane, the fiscal cost of such a significant transaction, which amounts to 1.85 MDH require registration fees.
The company operates throughout the chain of manufacture of the drug
Established in 1953, Bottu SA is a leading pharmaceutical Moroccans but also one of the largest with 31 million units sold in 2009. In early 1980, Ezzedine Berrada, current president and his family took control in the margins of the withdrawal of French shareholder namesake. With a workforce of around 400 employees, the company operates in all of the medication: Import raw materials or finished products to the marketing of proprietary pharmaceutical and para. During the last decade, the financial performance of this laboratory has continued to improve with a turnover that has tripled between 1999 and 2009 amounting to 396 million dirhams and net income has jumped from 133 % to 49.6 million dirhams. Should he cross the ruddy, Bottu strengthen the pharmaceutical sector values the Casablanca Stock Exchange which already has two representatives, and PROMOPHARMA SOTHEMA, whose combined market capitalization of 2.8 billion dirhams.
source hibapress.com
0 comments:
Post a Comment